Flexible Flat-Rate Plans
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
DrugPatentWatch Database Preview
LIPITOR Drug Profile
« Back to Dashboard
This drug has sixty-four patent family members in thirty-six countries.
The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
Summary for Tradename: LIPITOR
| Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 11 |
| Drug Prices: : | see details |
Pharmacology for Tradename: LIPITOR
| Drug Class | HMG-CoA Reductase Inhibitor |
| Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Clinical Trials for: LIPITOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-001 | Dec 17, 1996 | RX | No | 5,969,156*PED | Jan 8, 2017 | Y | |||||||||||||||||||
Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | RX | Yes | 5,969,156*PED | Jan 8, 2017 | Y | |||||||||||||||||||
Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-002 | Dec 17, 1996 | RX | No | 5,969,156*PED | Jan 8, 2017 | Y | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Patents for Tradename: LIPITOR
These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | 5,686,104*PED | <disabled> | ||||||||||||||||||||||
Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-003 | Dec 17, 1996 | 5,273,995*PED | <disabled> | ||||||||||||||||||||||
Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-001 | Dec 17, 1996 | 4,681,893*PED | <disabled> | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
International Patent Family for Tradename: LIPITOR
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spain | 2233526 | <disabled in preview> | |||||||||||||||||||||||||||
| Colombia | 4700443 | <disabled in preview> | |||||||||||||||||||||||||||
| South Korea | 100389518 | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Supplementary Protection Certificates for Tradename: LIPITOR
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0048 | France | <disabled> | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 | ||||||||||||||||||||||||||
| /1997 | Austria | <disabled> | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 | ||||||||||||||||||||||||||
| 545 | Luxembourg | <disabled> | PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
For more information try a trial or see the database preview and plans and pricing
How are People Using DrugPatentWatch?
To get accurate and reliable patency status in Saudi Arabia and Middle East countries
— Director, business development, Saudi Arabia
To identify business opportunities and check patent rights
— Managing director pharmaceutical company, Morocco
To know the patent status of branded drugs to assist with reserve planning for large claims
— Medical director at managed care organiziation, USA
To get yearly lists of patent expirations
— Analyst, Russia
To get information on expired patents
— Patent Attorney, USA
To gain knowledge on formulations of different drugs
— Product development officer, Pharmaceutical company, Bangladesh
To identify branded drug patent expiration and generic market entry
— CRO project manager, Portugal
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639
